@article{3202432, title = "Haemostatic profile of riboflavin-treated apheresis platelet concentrates.", author = "Petrou, Eleni and Nikolopoulos, Georgios K. and Kriebardis, Anastasios G. and Pantavou, Katerina and Loukopoulou, Electra and Tsantes, Andreas G. and Georgatzakou, Hara T. and Maratou, Eirini and Rapti, Evdoxia and Mellou, Sofia and Kokoris, Styliani and Gialeraki, Argyri and Tsantes, Argirios E.", journal = "Blood transfusion = Trasfusione del sangue", year = "2021", doi = "10.2450/2021.0089-21", abstract = "BACKGROUND: The haemostatic activity of platelet concentrates (PCs) treated with pathogen reduction technology (PRT) remains a subject of debate. Our aim was to investigate the effect of Mirasol PRT on the haemostatic properties of PCs stored in plasma. MATERIAL AND METHODS: Untreated and Mirasol-treated platelets stored in plasma and derived from ten split double-dose apheresis PCs were evaluated in vitro on days 1, 3 and 5 post collection for functionality, microparticle procoagulation activity (MPA), endogenous thrombin potential (ETP), and haemostatic profile using rotational thromboelastometry (ROTEM). RESULTS: P-selectin expression was significantly higher in Mirasol-treated platelets compared with untreated counterparts on days 3 and 5 (p=0.003 and p=0.002, respectively). Clot strength, as shown by EXTEM maximum clot firmness (MCF), was significantly lower in the Mirasol-treated platelets at all time points (days 1, 3, 5) than in untreated platelets (p=0.009, p<0.001, p<0.001, respectively). There was a considerable increase in MPA over time (p<0.001) and this was significantly higher in the Mirasol-treated platelets on day 5 (p=0.015). A notable acceleration of decrease in ETP values was observed for Mirasol-treated PCs over time (p<0.001), with significant differences between PRT-treated and untreated PCs on days 3 and 5 (p=0.038 and p=0.019, respectively). Clot strength attenuation was significantly associated with pH reduction (p<0.001, Spearman’s rho: 0.84), increased microparticle procoagulant activity (p<0.001, Spearman’s rho: -0.75), and with decreased ETP (p<0.032, Spearman’s rho: 0.41). DISCUSSION: Increased platelet activation induced by PRT treatment leads to a decrease in in vitro haemostatic capacity as seen by reduced clot strength and thrombin generation capacity over time. The clinical relevance of this needs to be investigated." }